Published 1985 | Version v1
Report Restricted

Radiopharmaceutical drug review process

Creators

  • 1. Food and Drug Administration, Rockville, MD

Description

To ensure proper radioactive drug use (such as quality, diagnostic improvement, and minimal radioactive exposure), the Food and Drug Administration evaluates new drugs with respect to safety, effectiveness, and accuracy and adequacy of the labeling. The IND or NDA process is used for this purpose. A brief description of the process, including the Chemical Classification System and the therapeutic potential classification, is presented as it applies to radiopharmaceuticals. Also, the status of the IND or NDA review of radiopharmaceuticals is given

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Additional details

Publishing Information

Imprint Title
Developing role of short-lived radionuclides in nuclear medical practice. DOE symposium series: 56
Journal Page Range
p. 54-57.
Report number
CONF-820523--

Conference

Title
International symposium on the developing role of short-lived radionuclides in nuclear medical practice.
Dates
3-5 May 1982.
Place
Washington, DC (USA).

INIS

Country of Publication
United States
Country of Input or Organization
United States
INIS RN
17019264
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Resource subtype / Literary indicator
Conference
Descriptors DEI
ORGANIZING; QUALITY CONTROL; RADIOPHARMACEUTICALS; RECOMMENDATIONS; US FDA
Descriptors DEC
CONTROL; DRUGS; LABELLED COMPOUNDS; MATERIALS; NATIONAL ORGANIZATIONS; RADIOACTIVE MATERIALS; US ORGANIZATIONS